UDK: 616.155.194-053.32-08-084
V. N. Osadshaya, L. K. Gavrikov, K. Y. Ponteleev
Кафедра педиатрии и неонатологии ФУВ ВолгГМУ
The article deals with prevention and treatment of anemic states in preterm infants by early administration (starting on the third day of life) of recombinant human erythropoietin (Eritrostim). The authors concluded that the administration of Eritrostim in a weekly dose of 200 IU / kg starting on the third day of life stimulates erythropoiesis and reduces the incidence of anemia; it can eliminate the need for red blood cell transfusion in preterm infants.
preterm, erythropoietin, anemia